TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07665970: An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB41 in Combination With SCTB39G With or Without Standard Therapy in Adult Patients With Advanced

Sponsor: Sinocelltech Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 112 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07665970 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07665970 Rescue Dossier →